
Thrombosis in the UK & Europe


1 in 4 people worldwide are dying from conditions caused by thrombosis¹.





This is greater than

the total number of people who lose their lives each year to AIDS, breast cancer, and motor vehicle crashes combined².



In Europe, there are more than **500,000** venous thromboembolism - related deaths every year².





Research suggests that venous thromboembolism is often preventable¹.



Over 90% of all inpatients admitted to NHS funded acute care hospitals are assessed for VTE risk in the UK³.



In the UK, VTE Exemplar Centres were created to recognise excellence in prevention care and encourage leadership and innovation in the field⁴.

Our portfolio consists of well-established injectable anticoagulants. All prefilled syringes are made and filled by Viatris' partner in France, EU.



97% participation of all colleagues globally engaged on **diversity**, equity and inclusion (DEI) learning5.



Our goal is to give patients access to high-quality antithrombotic medicines, making our contribution to diminish preventable suffering or death due to thromboembolism.

ThrombosisConnect



NON-2024-1877. October 2024

References: 1. World Thrombosis Day, What is Thrombosis? <u>https://www.worldthrombosisday.org/-</u>

know-thrombosis/what-is-thrombosis/. Last accessed October 2024.

2. World Thrombosis Day, Blood Clots: The Common Killer You Might Be Ignoring 2016 https://www.world-

thrombosisday.org/blood-clots-common-killer-you-might-be-ignoring/. Last accessed October 2024. 3. VTE Risk Assessment 2019/20. England NHS. https://www.england.nhs.uk/statistics/statistical-workar-

eas/vte/vte-risk-assessment-2019-20/. Last accessed October 2024

4. VTE Network Website https://vte-network.org/exemplar-centres/. Last accessed October 2024. 5. 2023 Viatris Sustainability Report.